3Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [ J ]. J Clin Oncol, 2006,24:2019-2027.
4Yeh E, Slanetz P, Kopans SB, et al. Prospective comparing of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer[ J]. Am J Roentgenol,2005,184 : 868-877.
5Berry DA, Cirrincione C, Henderson IC, et, al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J]. JAMA, 2006, 295 ( 14 ) : 1658- 1667.
6Campiglio M, Somenzi G, Olgiati C, et al. Role of proliferation in HER2 status predicted response to doxorubicin [ J ]. Int J Can, 2003,105 (4) :568-573.
7Jukkola A, Bloigu R, Soini Y, et al. C-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease [ J ]. Eur J Cancer,2001,37 (3) :347-354.
8Nigo YI, Yamashita M, Hirahara K, et al. Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function [ J ]. Proc Natl Acad Sci USA,2006, 103 (7) :2286-2291.
9Gregory RK, Pourles TJ, Salter J, et al. Prognoatic relevance of CerbB-2 express following neoadjuvant chemotherapy in patients in a randomized trial of neoadjvant versus adjuvant chemoendocrine therapy[ J ]. Breast Cancer Res Treat ,2000,59 (2) : 171-175.
10Pritchard KI, Seperherd LE, O'Malley FP, et al. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy [ J ]. N England J Med,2006:354:2103-2014.
